Representing more than 35,000 oncology professionals from 170 countries worldwide, ESMO is a reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE.
when we see vitamins and various crafting of health gain more understanding and market power... the feedback loops into populations and methodologies and value... lead reimbursements.... the interdisciplinary work and rights of individuals and groups are paramount to effective better.
🎶🎵 On Wisconsin 🎵🎶 •Is there an update on the roadmap? 🤔 •Law + Healthcare 🙌🏼🙏🏼 •GAPRI Strategy 🎉 •Hospice or Home Healthcare 🤔 •Local Fellowship 🫂 🙏🏼 •Amen Juice from The Biblical Nutritionist ❤️🥳 •Medical Mushrooms • (20) Hydrocodone is not enough and that's even if it's given as a placebo. 🤯 Thank you for this video 11 years ago. Cancer Pain is a real hell experience. In advance, Id like to thank Jesus Christ for the healing that's coming. 🙏🏼 ❤ Minister Stefanie Colonius, MMHCA 💖 John 3:16 KJV 💖
I’m looking for thymoma medicine like pill form to slow the growth . I can’t find anything type of therapy’s like that . Iv lost my left lung half my diaphragm within two years of my diagnosis ! I’m only 44
CAN YOU PPST 1 HOU 40 MINUTES CRONIC PAIN HOW OPIATES WORKS MOST CONUN DOSAGES ON CRONIC PAIN PACIENTS OUTSIDE CANCER THIS MOST DISSEASES OPIATES USE MOST ARTITHS OSTEOARTRITHS FYBROMYALGIA LOW BACK PAIN BONE DISSEASES ETC A FULL OPIATES CRONIC PAIN PROGAM? I suffer 24 hours pain just 28 years so sad dont want continue living aoo much suffering
I totally agree. I am a young mother and for me being able to take part in virtual meetings is sometimes much more challenging than previous, when I had to travel. I hope it will change
That's true. I am 31 year old woman and a mother of 4 year old boy. I have stayed at home since March this year because of pandemic. In January i had planed to prepare my PhD thesis and some papers during this few months and imagine how many things I could not do because of this situation. I hope I will continue my work and development in the near future, however this situation had a huge impact on my career. Thank you for this video. Now I feel that somewhere in the world are great people understanding my situation. Best regards. Zuzanna
Its nice that these new targeted drugs (BRAF inhibitors, MEK inhibitors) exist. But patient should NEVER be given them as a first-line therapy for metastatic melanoma. These drugs cannot cause complete and durable regressions of the tumors; only immunotherapies can do that. Patients should try a checkpoint inhibitor (anti-CTLA-4, anti-PD1), high dose interleukin-2, or adoptive cell transfer of infiltrating lymphocytes first. If one or more of these immune therapy attempts fail, then targeted inhibitors (BRAF, MEK) are a good fallback. These drugs can give a patient a few extra months to get their affairs in order and take a nice vacation before the melanoma inevitably becomes resistant and comes roaring back.
I disagree. Patients with fast-growing BRAF positive tumours might have not have the time to respond to Ipilimumab and anti-PD1 antibodies are currently not readily available first-line. IL-2 is not widely used in Europe and comes with an undesirable side effect profile. The therapeutical approach therefore needs to be tailored to the specific patient's situation and an initial salvage therapy with BRAF/MEK inhibition might provide a much better starting point for immunotherapy- giving a patient the chance to profit from the latter's long-term benefits. We need smart, undogmatic approaches how to play to the strengths of the different therapeutical groups and how to mitigate their shortcomings- like the onset of resistance with targeted therapy and the lag until first benefit associated with immunotherapies. Melanoma has the dubious honour of being one the most heterogeneous and genetically instable cancers making one-size-fits-all therapeutical approaches very unlikely to work.
